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NMDA receptor (NMDAR)-induced excitotoxicity is thought to contribute to the cell death associated with
certain neurodegenerative diseases, stroke, epilepsy, and traumatic brain injury. Targeting NMDARs thera-
peutically is complicated by the fact that cell signaling downstream of their activation can promote cell sur-
vival and plasticity as well as excitotoxicity. However, research over the past decade has suggested that
overactivation of NMDARs located outside of the synapse plays a major role in NMDAR toxicity, whereas
physiological activation of those inside the synapse can contribute to cell survival, raising the possibility
of therapeutic intervention based on NMDAR subcellular localization. Here, we review the evidence both sup-
porting and refuting this localization hypothesis of NMDAR function and discuss the role of NMDAR localiza-
tion in disorders of the nervous system. Preventing excessive extrasynaptic NMDAR activation may provide
therapeutic benefit, particularly in Alzheimer disease and Huntington disease.Introduction
More than five decades ago it was discovered that systemic
glutamate injections can destroy retinal tissue in the inner
layers (Lucas and Newhouse, 1957), providing the first evi-
dence for the toxic effects of glutamate. This ‘‘excitotoxicity,’’
a term coined by John Olney over a decade later, is now known
to occur throughout the brain (Olney, 1969), is dependent on
calcium influx (Choi, 1987) through N-methyl-D-aspartate
(NMDA) ionotropic glutamate receptors (Choi et al., 1988),
and is implicated in a variety of neurological conditions (Dong
et al., 2009). Unfortunately, treating disorders of the nervous
system with general NMDA receptor (NMDAR) blockers is
associated with unacceptable side effects, largely owing to
the paradoxical involvement of NMDAR signaling in both cell
death as well as cell survival and plasticity (Hardingham and
Bading, 2003); therefore, early clinical trials for NMDAR antag-
onists have been disappointing. However, a more recent
‘‘localization hypothesis’’ of NMDARs offers new promise in
differentiating these dramatically different downstream effects
of NMDAR activation. In its simplest form, this hypothesis
suggests that the activation of synaptic NMDARs promotes
cell survival, while activation of those outside of the synapse
(extrasynaptic) promotes cell death signaling (Hardingham
et al., 2002). With some notable recent exceptions (Papouin
et al., 2012; Wroge et al., 2012; Zhou et al., 2013b), the locali-
zation hypothesis has been supported by numerous studies
and is further substantiated by the observation of elevated
extrasynaptic NMDAR expression and/or activation in disease
states. In this Review, we will briefly discuss evidence for (as
well as against) the NMDAR localization hypothesis. Key
signaling pathways involved in this dichotomous NMDAR func-
tion will be highlighted as well as their respective roles in
synaptic plasticity. While much of this literature has been excel-
lently reviewed elsewhere (Hardingham and Bading, 2010), we
will then focus primarily on the contribution of extrasynapticNMDARs to chronic neurodegenerative disease and acute
neurological insults.
Extrasynaptic NMDARs: Signaling Pathways and
Synaptic Plasticity
Downstream Signaling from Synaptic and Extrasynaptic
NMDARs
If synaptic and extrasynaptic NMDARs play different roles in cell
survival and cell death, it follows that these two receptor popula-
tions must trigger different effects inside the cell subsequent
to their activation. This idea has received tremendous support
by studies that selectively activate synaptic or extrasynaptic
NMDARs; the former generally being achieved through pharma-
cological (4-aminopyridine [4-AP] to block K+ channels, and/or
bicuculline to block GABAergic inhibition) or electrical enhance-
ment of synaptic activity and the latter by synaptic NMDAR
preblock with MK-801 followed by exogenous NMDA applica-
tion (Figure 1A). Memantine, a noncompetitive, moderate affinity
NMDAR antagonist with fast on/off kinetics, has also been used
to assess the contribution of extrasynaptic NMDAR activity to
cell signaling and death, as it has been shown to preferentially
block tonically activated extrasynaptic NMDARs rather than
phasically activated synaptic NMDARs (Xia et al., 2010). Using
the above methodology, it has been shown that selective synap-
tic NMDAR stimulation increases extracellular signal-regulated
kinase 1/2 (ERK1/2) activation, cAMP response element-binding
protein (CREB) phosphorylation and brain-derived neurotrophic
factor (BDNF) expression, enhances antioxidant defense, and
provides neuroprotection, whereas extrasynaptic NMDAR stim-
ulation does the opposite (Hardingham et al., 2002; Hardingham
and Bading, 2010; Figure 1B). Nuclear calcium, an important
regulator of gene expression, plays a key role in the prosurvival
effects of synaptic stimulation and is disrupted by extrasynaptic
NMDAR activity (reviewed in Bading, 2013). Furthermore,
distinct isoforms of calcium-dependent proteases calledNeuron 82, April 16, 2014 ª2014 Elsevier Inc. 279
A B Figure 1. Synaptic and Extrasynaptic
NMDARs Associate with Different
Intracellular Signals
(A) Typical experimental setup to selectively stimu-
late synaptic or extrasynaptic NMDARs. Bicuculline
alone or with 4-aminopyridine (4-AP) is used to
enhance network activity, thereby increasing the
presynaptic release of glutamate. Such network
activity is believed to stimulate only synaptic re-
ceptors as any spillover would be quickly taken up
by glutamate transporters (not shown). When the
irreversible (but see McKay et al., 2013), use-
dependent NMDAR antagonist MK-801 is applied
under conditions of bicuculline and/or 4-AP treat-
ment, selective inhibition of synaptic NMDARs can
be attained. After washout of the unbound MK-801,
bath application of NMDA can now act selectively
on extrasynaptic receptors. This method is widely
used to quantify the relative amount of synaptic and
extrasynaptic NMDAR current as well as to identify
intracellular signaling downstream of selective
synaptic or extrasynaptic NMDAR activation.
(B) Using similar methodology, it has been shown
that stimulation of synaptic NMDARs activates prosurvival and inhibits prodeath intracellular signaling, whereas extrasynaptic NMDAR activation does the
opposite. Black and red text denotes an increase and decrease, respectively, in the activation, expression, or function of a particular intracellular signal after
selective NMDAR stimulation. For greater detail, see Hardingham and Bading (2010). See text for references.
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tic NMDAR stimulation, with the former activating m-calpain and
the latter activating m-calpain. Interestingly, m-calpain, but not
m-calpain, was shown to result in proteolysis of striatal-enriched
protein phosphatase (STEP), with subsequent activation of p38
mitogen-activated protein kinase (p38MAPK) and cell death
(Wang et al., 2013; Xu et al., 2009), providing further support
for the deleterious nature of extrasynaptic NMDAR activity.
Any shift in balance to reduce synaptic or enhance extrasynaptic
NMDAR signaling may be detrimental to neuronal health.
How can NMDAR activation at the cell surface act in the
nucleus to influence gene expression in a manner that reflects
the precise membrane localization at which the signal origi-
nates? A new study (Karpova et al., 2013) sheds some light on
this mystery by demonstrating a synaptic NMDAR-driven,
ERK1/2-dependent phosphorylation of a protein known as
Jacob. Specific synaptic NMDAR stimulation results in Jacob
phosphorylation by ERK1/2 and long-distance transport of
phosphorylated Jacob to the nucleus. Conversely, extrasynaptic
NMDAR stimulation fails to phosphorylate Jacob yet still induces
nuclear translocation, resulting in synaptic- and extrasynaptic-
induced translocation of phosphorylated and nonphosphory-
lated Jacob to the cell nucleus, respectively. In support of the
NMDAR localization hypothesis, when in the nucleus, phosphor-
ylated Jacob is associated with elevated phospho-CREB
(p-CREB), BDNF, and Arc3.1 levels, while nonphosphorylated
Jacob is associated with reduced p-CREB, dendritic complexity,
and synaptic connectivity (Dieterich et al., 2008; Karpova et al.,
2013). As ERK1/2 is known to be activated and inactivated by
synaptic and extrasynaptic NMDARs, respectively (Ivanov
et al., 2006), ERK1/2 and subsequent Jacob phosphorylation
appears to play a major role in communicating the origin of
NMDAR activity to the nucleus. A list of some of the intracellular
factors that are differentially influenced by location-based
NMDAR signaling is shown in Figure 1 and is reviewed in greater
detail in Hardingham and Bading (2010).280 Neuron 82, April 16, 2014 ª2014 Elsevier Inc.Synaptic and Extrasynaptic NMDARs: Role in Synaptic
Plasticity
Synaptic plasticity permits the regulated strengthening or weak-
ening of specific connections in an organized fashion and is well
accepted to represent the neurological underpinnings of learning
and memory. The reliance on NMDARs of various forms of long-
term potentiation (LTP) and long-term depression (LTD) has
been long established and recent evidence implicates differen-
tial roles for synaptic and extrasynaptic NMDARs in synaptic
plasticity. Conditions that increase the extrasynaptic glutamate
concentration, including increased stimulation intensities,
knockout or inhibition of the glial glutamate transporter, or exog-
enous applications of NMDA, can all impair LTP (Izumi et al.,
2008; Katagiri et al., 2001; Li et al., 2011). This inhibition of LTP
can be reversed by NMDAR antagonists, suggesting that extra-
synaptic NMDARs can obstruct activity-dependent plasticity.
Intriguingly, when synaptic receptors are preblocked with MK-
801, a theta-burst simulation protocol that normally generates
a potentiating effect can instead produce LTD, suggesting that
selective activation of extrasynaptic NMDARs induces LTD (Liu
et al., 2013). In a recent study by Papouin and colleagues, spe-
cific enzymes targeting the degradation of either D-serine or
glycine were used to show that D-serine and glycine act specif-
ically as endogenous coagonists at synaptic and extrasynaptic
NMDARs, respectively (Papouin et al., 2012; but see Rosenberg
et al., 2013 and below). The authors took advantage of this
discrimination and used D-serine degradation to isolate extrasy-
naptic NMDARs and glycine degradation to isolate synaptic
NMDARs to study the contribution of each receptor population
to Hebbian forms of plasticity. When D-serine was degraded,
thereby inhibiting synaptic NMDARs, the magnitude of LTP
expression was attenuated, suggesting a key role for synaptic
NMDARs in LTP. On the other hand, degradation of glycine
had no effect on LTP, suggesting that extrasynaptic NMDAR
activity is not required for LTP induction. In contrast, both syn-
aptic and extrasynaptic NMDARs are required for full LTD
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extrasynaptic NMDARs are inhibited by glycine degradation
(Papouin et al., 2012).
Location, Location. Subunit Composition
NMDARs assemble as heterotetramers with two obligatory
GluN1 subunits in combination with two additional GluN2
(GluN2A–GluN2D) and/or GluN3 (GluN3A–GluN3B) subunits, re-
sulting in a heterogeneous population of NMDARs with diverse
pharmacological properties, kinetics, and downstream signaling
pathways (Cull-Candy et al., 2001; Paoletti et al., 2013; Paoletti
and Neyton, 2007; Sanz-Clemente et al., 2013). The large major-
ity of NMDARs in the CNS assemble as diheteromers of GluN1/
GluN2A or GluN1/GluN2B, or as a triheteromer of GluN1/
GluN2A/GluN2B. Subunit expression is developmentally regu-
lated, with GluN2B-containing NMDARs dominating early in
development and GluN2A-containing NMDARs dominating in
adulthood.
A controversial theory postulates dramatic localization differ-
ences between GluN2A- and GluN2B-containing receptors, in
that the former is found within, and the latter outside, the
synapse. While it is clear that the partition is not absolute—
GluN2B can be found synaptically and vice versa (Harris and
Pettit, 2007; Liu et al., 2004; Petralia et al., 2010; Thomas
et al., 2006)—a GluN2A/synaptic and GluN2B/extrasynaptic
bias has received a fair amount of support over the years (Groc
et al., 2006;Martel et al., 2009; Sanz-Clemente et al., 2013; Tovar
and Westbrook, 1999). Interestingly, GluN2A-type NMDARs
generally have a greater association with cell survival, whereas
GluN2B-type NMDARs are linked to cell death signaling (Lai
et al., 2011); therefore, a ‘‘subunit hypothesis’’ can work in tan-
demwith the ‘‘localization hypothesis’’ to form a ‘‘unified hypoth-
esis’’ (Lai et al., 2011) in that extrasynaptic GluN2B-containing
NMDARs may preferentially signal to cell death after activation
in comparison to synaptic GluN2A activation. A recent elegant
study, using chimeric constructs of GluN2 subunits and a
knockin mouse model in which the C-terminal tail of GluN2A
was swapped for that of GluN2B, provided convincing evidence
that intracellular signaling via the GluN2B C terminus is a large
contributor to NMDA-induced toxicity (Martel et al., 2012).
A unified hypothesis that associates GluN2B/extrasynaptic
and GluN2A/synaptic NMDARs with cell death and survival,
respectively, is indeed an attractive one in its simplicity and is
supported by numerous studies. However, before proceeding
to a discussion regarding the role of NMDAR location in dis-
ease, it must be noted that recent findings have suggested a
significant role for GluN2A and synaptic NMDARs in excitotoxic
cell death under certain experimental conditions (Papouin et al.,
2012; Wroge et al., 2012; Zhou et al., 2013a, 2013b), and
perhaps it should not be surprising that a universal rule of
NMDAR toxicity has yet to be agreed upon. Between-study
comparisons are made difficult by the variety of experimental
approaches (e.g., including analysis of necrotic versus
apoptotic cell death), the use of a wide range of neurodevelop-
mental stages, the lack of pharmacological means to definitively
distinguish NMDAR subtypes, and a general disregard for the
existence of GluN1/GluN2A/GluN2B triheteromers, which have
been recently estimated to account for as much as two-thirds
of synaptic NMDAR currents (Tovar et al., 2013). Specifically,although there are inhibitors such as ifenprodil and Ro 25-
6981 that show high selectivity for GluN2B-containing
NMDARs, pharmacological agents specific for GluN1/GluN2A
diheteromers or GluN1/GluN2A/GluN2B triheteromers are not
well developed. Even within the obligatory GluN1 subunit, there
are eight different isoforms which show region-specific expres-
sion patterns and can alter NMDAR pharmacological and
trafficking properties (Paoletti et al., 2013). With regards to
developmental stage, it is estimated that in cultured neurons,
as many as 90% of the NMDARs are extrasynaptic after
1 week in vitro, whereas this number is reduced to 50% or
less by 2 weeks (reviewed in Gladding and Raymond, 2011),
making it difficult to draw conclusions regarding the contribu-
tion of synaptic receptors to cell survival or death from studies
using immature culture systems. Furthermore, as extrasynaptic
NMDARs are more likely to receive tonic activation than the
phasic activity patterns generally seen at synaptic receptors,
differences in downstream signaling may depend in part on
the tonic or phasic nature of NMDAR stimulation. Lastly, recent
evidence opposing the localization hypothesis relied heavily on
the selectivity of D-serine for synaptic and glycine for extrasy-
naptic NMDARs as a means to isolate NMDARs based on their
location (Papouin et al., 2012). However, this interpretation is
complicated by the demonstration that both glycine and
D-serine can be released through neuronal Asc-1 transporters
and act as synaptic NMDAR coagonists (Rosenberg et al.,
2013). While it is true that acute D-serine degradation dramati-
cally reduces synaptic NMDAR-mediated current, and that
such a treatment offers significant neuroprotection (Mothet
et al., 2000; Papouin et al., 2012; Shleper et al., 2005), it has
been suggested that the possibility of D-serine also acting as
a coagonist at extrasynaptic sites has not been definitively ruled
out (Gray and Nicoll, 2012).
From the conflicting data it is suggested that some hierarchy
of NMDAR excitotoxicity exists in which developmental stage,
NMDAR subunit composition, type (tonic/phasic) and duration
of activation, as well as NMDAR localization can all play a role.
In this Review, we will focus on the localization aspect of this
hierarchy and discuss the contribution of extrasynaptic NMDARs
to cell death in diseases of the nervous system.
Extrasynaptic NMDARs and Diseases of the Nervous
System
The pathogenesis of more and more CNS disorders is being
attributed, at least in part, to extrasynaptic NMDAR activity.
Some notable examples include the neurodegenerative
Alzheimer disease (AD) and Huntington disease (HD), as well
as ischemia/hypoxia, traumatic brain injury (TBI), and epilepsy.
Enhanced glutamatergic activity at extrasynaptic sites can occur
in numerous ways, including a failure of glutamate uptake, glio-
transmission, reverse operation of the glutamate transporters,
an increase in presynaptic glutamate release probability, aber-
rant burst firing of presynaptic inputs, or an increase in the
number and/or stability of NMDARs at extrasynaptic sites.
Many of these disorders also share common signaling pathways
downstream of extrasynaptic NMDAR activity that contribute
to neurotoxicity. Therefore, understanding the neurobiology
underlying enhanced extrasynaptic NMDAR activation andNeuron 82, April 16, 2014 ª2014 Elsevier Inc. 281
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developing treatment strategies for neurologic disease.
Alzheimer Disease
Evidence for an Extrasynaptic NMDAR Involvement in AD. AD is
the most common form of dementia and the most common
neurodegenerative disease. It is estimated that over five million
Americans have AD. This number has risen by over 60% in the
last decade and is expected to more than double by 2050
(Alzheimer’s Association, 2012); such prevalence rates have
ignited considerable interest in the neurobiology of AD. Over-
whelming evidence supports the idea that soluble oligomers of
the amyloid-beta protein (Ab) and hyperphosphorylation of tau
protein represent themajor toxic species underlying the synapse
loss, plasticity and cognitive deficits, and eventual neurodegen-
eration associated with AD (Danysz and Parsons, 2012; Gong
and Iqbal, 2008). Of interest to the present Review is that recent
investigation into the neurotoxic effects of oligomeric Ab and
phosphorylated tau has identified a critical involvement of
NMDARs and, in particular, extrasynaptic NMDARs.
Ab negatively regulates the number of NMDARs at postsyn-
aptic sites, thereby disrupting the balance between synaptic
and extrasynaptic NMDAR activity. When applied to cultured
cortical neurons, Ab enhances NMDAR endocytosis and de-
creases synaptic expression (Snyder et al., 2005), consistent
with the finding that calcium influx through NMDARs after gluta-
mate uncaging at single spines is significantly reduced after Ab
treatment (Shankar et al., 2007). Interestingly, Snyder and col-
leagues were unable to detect a difference in the extrasynaptic
staining of NMDARs in response to Ab (Snyder et al., 2005),
suggesting that the Ab-induced NMDAR endocytosis may be
specific to synaptic NMDARs and may subsequently decrease
downstream prosurvival signaling. More recent biochemical
fractionation experiments are in agreement with this possibility;
hippocampal slices treated with Ab-containing conditioned
media exhibit reduced expression of PSD-95 and GluN2B in
synaptic but not extrasynaptic fractions (Li et al., 2011). Similarly,
Ab decreases synaptic glutamatergic currents in autaptic hippo-
campal cultures (Talantova et al., 2013). Thus, Ab appears to
specifically promote the internalization of synaptic and not extra-
synaptic NMDARs, altering the balance between synaptic and
extrasynaptic NMDAR signaling.
While immunohistochemical and biochemical data suggest
that Ab does not redistribute NMDARs from synaptic to extra-
synaptic sites in a manner that enhances the quantity of extra-
synaptic NMDARs (Li et al., 2011; Snyder et al., 2005), it is well
established that Ab oligomers can facilitate tonic glutamate
buildup in the extracellular space, activating extrasynaptic
NMDARs. D-[3H]-aspartate binding (a marker of glutamate
transporters) is reduced in AD brains (Masliah et al., 1996) and
a reduction in the expression of glutamate transporters is
observed both in human tissue from AD patients (Chen et al.,
2011) and animal models of AD (Masliah et al., 2000; Schallier
et al., 2011). Moreover, studies investigating the effect of Ab on
hippocampal neurons found an enhancement of presynaptic
glutamate release, an inhibition of glial glutamate uptake, and a
general increase in the concentration of extracellular glutamate
(Abramov et al., 2009; Danysz and Parsons, 2012). A recent
study also showed that Ab triggers ubiquitination and subse-282 Neuron 82, April 16, 2014 ª2014 Elsevier Inc.quent reduction in the surface expression of the glial glutamate
transporter GLT-1, dramatically diminishing the rate at which
synaptically released glutamate is cleared (Scimemi et al.,
2013). When synaptic NMDARs are preblocked with MK-801,
Ab from a variety of sources, including cell culture, human brain
extracts, and synthetic Ab, can still induce an NMDAR-depen-
dent current (Li et al., 2011; Talantova et al., 2013). As this
effect can be blocked by Ro25-6981, it suggests that Ab results
in an increased activation of GluN2B-containing extrasynaptic
NMDARs.
In addition to reducing glutamate uptake, Ab can also
contribute to extrasynaptic NMDAR activation by triggering
glutamate release from glial cells. By measuring whole-cell
currents from cultured microglia, Noda and colleagues demon-
strated that outward currents (representing the corelease of
glutamate and sodium) in response to potassium stimulation
are significantly larger in cultures treated with Ab (Noda et al.,
1999). The authors also measured glutamate concentration in
the conditioned media and confirmed that Ab-treated cultures
respond to potassium stimulation with an enhanced release of
glutamate. A more recent study (Talantova et al., 2013)
employed a novel fluorescent glutamate sensor called Super-
GluSnFr to measure glutamate release dynamics in cultured
astrocytes with precise spatial and temporal resolution. The
authors observed a rapid calcium-dependent increase in gluta-
mate release from pure astrocyte cultures in response to oligo-
meric but not monomeric Ab application. Interestingly, this effect
is dependent on the activation of a7 nicotinic acetylcholine re-
ceptors, consistent with previous work demonstrating that Ab
directly binds these receptors (Wang et al., 2000). Thus, in addi-
tion to reducing glutamate uptake, Ab also has a direct effect on
glial glutamate release, further increasing the probability of ex-
trasynaptic NMDAR activation.
Synaptic activity and exocytosis drives the release of Ab
into the extracellular space (Cirrito et al., 2005) and synaptic
versus extrasynaptic NMDAR activation can differentially
influence the production and/or secretion of Ab. General
NMDAR activation by bath NMDA application to cultured
cortical neurons increases the production and secretion of Ab
by upregulating the expression of amyloid precursor proteins
(APPs) containing a Kunitz protease inhibitory domain (KPI;
Lesne´ et al., 2005). This KPI domain associates with and in-
hibits the a-secretase ADAM17 (also known as tumor necrosis
factor a converting enzyme [TACE]) and promotes b-secretase
cleavage of APP into toxic Ab fragments (Lesne´ et al., 2005).
Interestingly, selective stimulation of extrasynaptic NMDARs
after synaptic NMDAR preblock still enhances KPI-containing
APPs and Ab production (Bordji et al., 2010). On the other
hand, stimulating synaptic receptors alone with bicuculline
and 4-AP increases BDNF mRNA and has no effect on KPI-
APP or Ab expression. In fact, synaptic NMDAR activity actually
increases a-secretase-mediated nonamyloidogenic processing
of APP (Hoey et al., 2009). This extrasynaptic NMDAR-medi-
ated production of Ab thus creates a toxic positive feedback
in which Ab promotes extrasynaptic NMDAR activity, which
stimulates further Ab production and secretion. Interfering
with this positive feedback may provide therapeutic benefit to
AD patients.
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andADPathogenesis. Many studies have identified key signaling
pathways involved in the pathogenesis of AD. Given the strong
evidence for enhanced extracellular glutamatergic tone in AD,
it is not surprising that significant overlap exists between the
signaling molecules implicated in AD and those influenced by
extrasynaptic NMDAR stimulation. CREB-mediated gene
expression is essential for cell survival and plasticity as well as
learning and memory, and CREB phosphorylation at serine-
133, which is required for its transcriptional activity, is decreased
in AD (Saura and Valero, 2011; Yamamoto-Sasaki et al., 1999),
and after extrasynaptic NMDAR stimulation (Hardingham et al.,
2002). Treatments such as rolipram and forskolin that increase
the cAMP signaling pathway can restore CREB phosphorylation
as well as the synapse loss and LTP deficits thought to
contribute to the cognitive deficit in AD (Smith et al., 2009; Vitolo
et al., 2002). Jacob translocates to the nucleus after Ab treat-
ment (Dieterich et al., 2008), most likely in the nonphosphory-
lated form, since phosphorylated Jacob is translocated after
synaptic NMDAR stimulation and is associated with BDNF,
CREB, and Arc signaling as well as neuroprotection (Karpova
et al., 2013). On the other hand, nonphosphorylated Jacob is
translocated after extrasynaptic NMDAR stimulation and is
associated with decreases in CREB activity, dendritic
complexity, and synaptic density (Karpova et al., 2013). Further-
more, the effect of Ab on Jacob translocation is completely
blocked by the GluN2B-specific antagonist ifenprodil (Ro¨nicke
et al., 2011), demonstrating that the Ab-induced Jacob translo-
cation is dependent upon GluN2B-containing NMDARs.
The neurotrophic factor BDNF can promote serine-133 CREB
phosphorylation through CaMKIV or ERK1/2 activation; more-
over, the BDNF gene is a CREB target (Tao et al., 1998), creating
a positive feedback between these two prosurvival factors. As
with CREB activity levels, BDNF is decreased in the brain
(Peng et al., 2005; Phillips et al., 1991), serum, and cerebrospinal
fluid (Laske et al., 2006) of human AD patients as well as in AD
mouse models (Blurton-Jones et al., 2009; Peng et al., 2009).
Notably, BDNF induction is suppressed by extrasynaptic
NMDAR activity (Hardingham et al., 2002). In a transgenic mouse
model of AD, much of the cognitive deficit can be restored after
stem cell implantation. Interestingly, this effect is dependent
upon BDNF release from the newly implanted cells, as the effect
ismimicked by recombinant BDNF and abolished by depletion of
BDNF from the stem cells (Blurton-Jones et al., 2009). Further-
more, cognition is improved despite a lack of improvement in
the Ab or tau pathology, suggesting an important role for
BDNF inactivation downstream of Ab and tau in AD pathogen-
esis (Blurton-Jones et al., 2009). Similarly, viral delivery of
CREB-binding protein (CBP) increases BDNF expression and
improves the cognitive deficits in an animal model of AD, without
effect on Ab or tau pathology (Caccamo et al., 2010). These
studies demonstrate that Ab and tau toxicity rely at least in
part on downstream negative effects on CREB and BDNF
signaling.
While the discussion thus far has centered on the link between
Ab and extrasynaptic NMDAR signaling, it is also well estab-
lished that hyperphosphorylation of the tau protein is critical to
AD pathogenesis (Gong and Iqbal, 2008). Tau phosphorylationlevels are up to four times higher in AD brains (Ko¨pke et al.,
1993) and Ab fails to induce its toxic effects in the absence of
tau (Rapoport et al., 2002). Although tau is phosphorylated at
many different sites, research has pointed to a few key kinases
that largely regulate its phosphorylation state in AD. Glycogen
synthase kinase 3b (GSK-3b) is one particular tau kinase that is
activated by Ab application (Hoshi et al., 2003) and contributes
to Ab-induced tau phosphorylation and toxicity (Tackenberg
et al., 2013). Interestingly, extrasynaptic NMDAR activation
exacerbates tau toxicity, and blockade of GluN2B-containing
NMDARs inhibits Ab-induced GSK-3b activation, tau phosphor-
ylation, and toxicity (Tackenberg et al., 2013). Similarly, fluores-
cent tracking experiments demonstrate that the Ab-dependent
impairment of axonal transport is significantly attenuated by
NMDAR antagonists or by GSK-3b inhibition (Decker et al.,
2010), further supporting a link between NMDARs and GSK-3b
activation. Selective synaptic NMDAR activation can inhibit
GSK-3b though Akt-mediated phosphorylation at serine-9 (Sor-
iano et al., 2006), suggesting a mechanism by which synaptic
NMDAR activation may be protective in AD.
A second tau kinase highly implicated in AD development is
cyclin-dependent kinase 5 (cdk5). Cdk5 activation is increased
after general glutamate application and glutamate-induced
toxicity can be rescued by a cdk5 inhibitor (Miao et al., 2012).
Recently, it was shown that Ab induces an extrasynaptic
NMDAR-dependent increase in nitric oxide (Talantova et al.,
2013), which can activate cdk5 through nitrosylation; this pro-
cess contributes to the harmful effects of Ab, including down-
stream transnitrosylation of dynamin-related protein 1 (Drp1)
that results in mitochondrial dysfunction, bioenergetic failure,
and synapse loss (Cho et al., 2009; Qu et al., 2011). Moreover,
nitrosylated cdk5 is enhanced in AD brains (Qu et al., 2011)
and thereby may also contribute to tau hyperphosphorylation.
Ab can also contribute to cdk5 activation through calpain-
dependent cleavage of p35 to p25, while inhibition of cdk5 or
calpain can reduce Ab toxicity (Lee et al., 2000). Thus, extrasy-
naptic NMDAR activation may promote tau phosphorylation
through various mechanisms. Indeed, selective activation of
extrasynaptic NMDARs after synaptic NMDAR preblock with
MK-801 enhances tau phosphorylation in cultured hippocampal
neurons (Talantova et al., 2013).
Additional data further support the link between extrasynaptic
NMDAR activity and AD pathogenesis. For example, caspase-3
(Talantova et al., 2013; Wang et al., 2004), FoxO3a (Qin et al.,
2008), and p38MAPK (Hensley et al., 1999; Wang et al., 2004)
are all associated with AD neuropathology and are also activated
by increased extrasynaptic NMDAR activity (Hardingham and
Bading, 2010). Furthermore, the oxidative stress induced by Ab
can be blocked bymemantine (De Felice et al., 2007), anNMDAR
antagonist that shows specificity for extrasynaptic over synaptic
NMDARs (Xia et al., 2010; but see Wroge et al., 2012), and
the impaired glutamate uptake in AD can be prevented by the
vitamin E derivative Trolox (Scimemi et al., 2013). Finally, it was
recently shown that phosphorylation of the histone protein
H2AX, which is a marker for DNA double strand breaks in
neurons, is increased after Ab application and that this increase
is dependent upon extrasynaptic NMDARs (Suberbielle et al.,
2013).Neuron 82, April 16, 2014 ª2014 Elsevier Inc. 283
Figure 2. Putative Mechanisms Underlying
NMDAR Toxicity in Alzheimer Disease
(1) Toxic soluble oligomers of Ab can bind directly to
a7 nicotinic acetylcholine receptors to trigger cal-
cium-dependent release of glutamate from astro-
cytes. This can result in increased extracellular
glutamate acting on extrasynaptic NMDARs. (2)
Glutamate transporter expression is decreased in
AD, resulting in impaired glutamate uptake that also
contributes to extrasynaptic NMDAR activation. (3)
Ab itself can bind to NMDARs and has been
suggested to directly activate them. Whether this
occurs preferentially at synaptic or extrasynaptic
sites remains to be seen. (4) Ab actions on a7
nicotinic channels can also promote synaptic
NMDAR internalization by activating protein phos-
phatase 2B (PP2B), which dephosphorylates
and activates STEP. Active STEP then de-
phosphorylates NMDARs at Y1472, resulting in syn-
aptic NMDAR internalization, further shifting the
balance toward extrasynaptic NMDAR signaling. (5)
As a result of enhanced extracellular glutamate,
extrasynaptic NMDARs are highly active. This gives
rise to nitric oxide (NO) production, which activates
cdk5 via S-nitrosylation. S-nitrosylated (SNO) cdk5
can transnitrosylate Drp1, which results in mito-
chondrial fragmentation. As cdk5 is a known tau
kinase, it is also possible that SNO-cdk5 contributes
directly to enhanced tau phosphorylation. Extra-
synaptic NMDAR activity also activates GSKb,
which contributes to tau hyperphosphorylation in
AD. (6) Elevated extrasynaptic NMDAR activity is
also associated with ERK1/2 inhibition (dephos-
phorylation) and the translocation of Jacob (likely in
its nonphosphorylated state) to the nucleus, where it has a negative effect on CREB-mediated transcription. The transcription factor FoxO3a is also translocated
to the nucleus in AD and after extrasynaptic NMDAR activity and may increase the expression of cell death genes. Extrasynaptic NMDAR activation is also linked
to increased expression of KPI domain-containing APP, which facilitates b-secretase (bsec) cleavage of APP into Ab, which can then be released to the
extracellular space in an activity-dependent manner. An enhancement of DNA double strand breaks (DSB) is observed in AD and is dependent upon extra-
synaptic NMDAR activity. AD is also associated with increased levels of p38MAPK (p38), which may arise as a result of extrasynaptic NMDAR-induced calpain
cleavage of STEP (from STEP61 to STEP33) and subsequent p38MAPK activation. See text for additional details and references.
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support for the notion that Ab oligomers from a variety of sources
and of varying concentrations can severely impair NMDAR-
dependent LTP at hippocampal CA1 and dentate gyrus synap-
ses both in vitro and in vivo (reviewed in Danysz and Parsons,
2012). As Ab can also increase the extracellular availability of
glutamate, it follows that the LTP deficit may result from an over-
stimulation of extrasynaptic NMDARs, as reviewed above.
Indeed, Ab-induced LTP inhibition can be prevented by GluN2B
antagonists at low concentrations that did not alter plasticity in
control conditions (Hu et al., 2009) or by preincubation with
memantine (Rammes et al., 2011). Similarly, Ro¨nicke and
colleagues found that GluN2B antagonists can block the detri-
mental effects of Ab on not only LTP but also on basal synaptic
transmission, network activity, and spine density (Ro¨nicke
et al., 2011). A more direct link to extrasynaptic receptors was
made recently when it was demonstrated that Ab-induced LTP
impairment could be ameliorated by decreasing extracellular
glutamate levels (Li et al., 2011). Notably, the LTP impairment
in AD can also be prevented by inhibition of p38MAPK or calpain
(Li et al., 2011), both of which are selectively activated by extra-
synaptic NMDARs.
In all, a large body of evidence supports a significant role for
enhanced extrasynaptic NMDAR activity in the pathogenesis of
AD. Some of the pathways and mechanisms discussed above
are summarized in Figure 2.284 Neuron 82, April 16, 2014 ª2014 Elsevier Inc.Huntington Disease
Evidence for an Extrasynaptic NMDAR Involvement in Hunting-
ton Disease. Huntington disease (HD) is an autosomal dominant
neurodegenerative disease caused by a CAG repeat expansion
in the gene encoding the huntingtin protein (Htt). This protein
(mutant huntingtin [mHtt]) results in deficits in synaptic signaling,
plasticity, and eventual cell death that is particularly striking in
the striatum. While the neurobiological consequences of mHtt
are broad and impact many aspects of cellular function (Zuccato
et al., 2010), recent advances in the field have highlighted an
important role of extrasynaptic NMDAR signaling in HD patho-
genesis (Milnerwood et al., 2010; Okamoto et al., 2009). Many
of the mechanisms and pathways related to enhanced NMDAR
signaling in HD are summarized in Figure 3 and discussed in
detail in the following sections.
In virtually all of the animal models available for the study of HD
(Pouladi et al., 2013), an increase in NMDAR-mediated currents,
particularly in striatal medium-sized spiny projection neurons
(SPNs), has been observed (Raymond et al., 2011). Moreover,
it is well established that mHtt increases neuronal susceptibility
to NMDA-induced toxicity (Fan and Raymond, 2007; Zeron
et al., 2002; Zhang et al., 2008). In fact, intrastriatal injections
of glutamate receptor agonists were initially used as a model
of HD due to their ability to recapitulate key features of the
disease (Beal et al., 1986; Coyle and Schwarcz, 1976). It is
now becoming clear that the major NMDAR contributors to
Figure 3. Putative Mechanisms Underlying
NMDAR Excitotoxicity in Huntington Disease
(1) Enhanced synaptic STEP signaling in HD can
result in NMDAR dephosphorylation at Y1472, pro-
moting lateral movement of NMDARs away from
synaptic sites. When outside the synapse,
enhanced calpain signaling in HD increases the
cleavage of the NMDAR C-terminal tail, which may
effectively reduce clathrin-mediated endocytosis,
thereby leaving more NMDARs at the extrasynaptic
surface. (2) The largely synaptic scaffolding protein
PSD-95 is elevated at extrasynaptic sites in HD and
associates with GluN2B subunits. This interaction is
required for the enhanced basal levels of p38MAPK
(p38) in HD. There is also an increased surface
expression of GluN3A-containing NMDARs due
to decreased endocytosis as a result of mHtt
sequestration of the endocytic adaptor PACSIN1.
Whether GluN3A subunits form the same or different
receptor complexes as GluN2B-containing
NMDARs remains to be seen. (3) GLT-1 depalmi-
toylation decreases its function in HD, resulting in
poor uptake of synaptically released glutamate,
thereby increasing the chances of extrasynaptic
NMDAR activation. (4) Enhanced extrasynaptic
NMDAR activity in HD increases Rhes, which
SUMOylates and disaggregates mHtt. Disaggre-
gation of mHtt is thought to increase its toxicity by,
for example, sequestering CBP and preventing its
nuclear entry and support of CREB-mediated gene
transcription. mHtt also acts in the nucleus to sup-
press PGC-1a expression by interfering with both
CREB and TAF4-mediated transcription. Reduced
PGC-1a can, in turn, increase extrasynaptic
NMDAR currents in a toxic positive feedback cycle.
Extrasynaptic NMDAR activation may also
contribute more directly to CREB shutoff and
decreased PGC-1a expression by an undetermined
mechanism. See text for details and references.
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Electrophysiological and biochemical approaches reveal an
increase in extrasynaptic NMDARs in the yeast artificial chromo-
some (YAC) mouse model of HD with 128 CAG repeats
(YAC128). Isolated NMDAR currents recorded from SPNs are
larger for YAC128 mice when high stimulus intensities, or the
glutamate transporter inhibitor DL-threo-b-Benzyloxyaspartic
acid (TBOA), are used to promote glutamate spillover. Further-
more, the expression level of GluN2B is increased in nonsynaptic
membrane fractions from YAC128 striatum and cortex (Milner-
wood et al., 2010). In primary neuronal culture, residual NMDAR
current after synaptic NMDAR preblock is increased in mHtt-
expressing neurons (Milnerwood et al., 2012; Puddifoot et al.,
2012), further suggestive of enhanced extrasynaptic NMDARs
in HD. GluN2B generally exhibits faster lateral diffusion than
GluN2A subunits, at least in cultured neurons (Groc et al.,
2006). However, in mHtt-expressing striatal neurons, there is
enhanced extrasynaptic localization of the scaffold PSD-95,
which associates more strongly with GluN2B, probably resulting
in greater stability of GluN2B-containing NMDARs outside the
synapse (Fan et al., 2009, 2012). Memantine, at low concentra-
tions, abolishes the enhanced sensitivity of mHtt-expressing
cultured neurons to glutamate-induced cell death (Okamoto
et al., 2009) and in YAC128 mice memantine treatment improves
motor performance and rescues striatal SPN loss (Milnerwood
et al., 2010; Okamoto et al., 2009). The importance of GluN2B-containing NMDARs in HD is demonstrated by the fact that ifen-
prodil can mimic the effect of memantine in alleviating the
enhanced susceptibility to excitotoxic insult associated with
mHtt expression (Okamoto et al., 2009; Zeron et al., 2002).
In addition to GluN2B NMDARs, recent evidence suggests
that HD is associated with an upregulation of surface GluN3A-
containing NMDARs as a result of mHtt-induced sequestration
of the endocytic adaptor protein PACSIN1 (Marco et al., 2013).
Since GluN3A expression negatively impacts synapse formation
and/or stabilization (Henson et al., 2010), increased expression
in HD can reduce the amount of prosurvival signaling occurring
through synaptic NMDARs. Notably, crossing HD mice with
mice lacking GluN3A receptors ameliorates many of the synap-
tic, neuropathological, and behavioral deficits associated with
HD (Marco et al., 2013). GluN3A overexpression is also known
to increase the amount of GluN2B at extrasynaptic sites,
possibly by forming a complex that includes GluN1 and GluN2B
together with GluN3A that anchors relatively poorly at the
postsynaptic density (Martı´nez-Turrillas et al., 2012). However,
it remains unclear whether the GluN3A present in HD striatal
tissue forms a complex with GluN2B subunits, or whether the
elevated GluN3A levels contribute to a separate, diheteromeric
GluN1-GluN3A receptor population.
Studies on the mechanisms underlying NMDAR mislocali-
zation in HD are ongoing and likely to involve alterations in
posttranslational modifications including phosphorylation,Neuron 82, April 16, 2014 ª2014 Elsevier Inc. 285
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reviewed elsewhere (Gladding and Raymond, 2011). Both cal-
pain-mediated cleavage of the GluN2B C terminus, as well as
STEP-induced regulation of GluN2B phosphorylation, contribute
to the change in the synaptic/extrasynaptic balance of striatal
GluN2B-containing NMDAR in presymptomatic YAC128 mice
(Gladding et al., 2012). In addition, HD has been linked to deficits
in palmitoylation of synaptic proteins (Young et al., 2012), partic-
ularly through an altered association between mHtt and the
palmitoyl acyltransferase DHHC17 (huntingtin interacting protein
14 [HIP14]; Huang et al., 2011; Singaraja et al., 2011). Palmitoy-
lation of NMDAR subunits influences their surface expression
and targeting to the synapse (Hayashi et al., 2009; Mattison
et al., 2012), and DHHC17 knockout mice share similar synaptic,
neuropathological and behavioral deficits with other HD mouse
models (Milnerwood et al., 2013; Singaraja et al., 2011). In light
of the enhanced PSD-95/GluN2B interaction in HD, it is worth
noting that palmitoylation of PSD-95 targets this scaffold to
synapses (Craven et al., 1999) and that PSD-95 palmitoylation
is decreased in DHHC17 knockout mice (Singaraja et al.,
2011). Thus, it is of interest for future studies to determine
whether altered palmitoylation of NMDARs and/or PSD-95 is
responsible for receptor mislocalization in HD.
As mentioned, mHtt expression imparts a wide variety of
cellular and synaptic effects and the increase in extrasynaptic
NMDAR expression is just one of many potentially toxic conse-
quences of mHtt expression. The glutamate transporter system
would normally prevent excess tonic glutamate buildup and sub-
sequent overactivation of extrasynaptic NMDARs. However, as
we have seenwith AD, HD is also associatedwith impaired gluta-
mate uptake. In the R6/2 model of HD that expresses the
N-terminal fragment of Htt with a pathological number of CAG
repeats, there is an early, presymptomatic decrease in the
expression of glial glutamate transporter GLT-1 mRNA in both
the striatum and cortex (Lie´vens et al., 2001). In contrast, there
have been mixed reports regarding the protein expression levels
of GLT-1 and other glutamate transporters, with some studies
showing decreased expression in HD (Faideau et al., 2010;
Lie´vens et al., 2001) and others showing no change (Huang
et al., 2010; Miller et al., 2008). Despite the lack of consensus
regarding glutamate transporter expression in HD, it is clear
that glutamate uptake by these transporters is impaired begin-
ning at presymptomatic stages of disease; this has been shown
byD-aspartate binding (Lie´vens et al., 2001), microdialysis (Miller
et al., 2008), and by measurements of synaptosomal glutamate
uptake (Huang et al., 2010; Lie´vens et al., 2001). Moreover, the
data are in agreement across HD animal models, and decreased
glutamate uptake is also observed in human HD brains (Cross
et al., 1986; Hassel et al., 2008). There is at least some regional
specificity as striatal uptake impairments appear first, followed
by the cortex. The cerebellum, which is largely spared in HD, is
also spared from deficient glutamate uptake (Huang et al.,
2010). Interestingly, when mHtt expression is restricted to astro-
cytes, glutamate uptake is still diminished relative to controls,
suggesting cell-autonomous effects of mHtt within astrocytes
(Huang et al., 2010). Moreover, aberrant firing of cortical afferent
neurons may also contribute to glutamate abundance in the HD
striatum (Cepeda et al., 2003). The finding that increasing GLT-1286 Neuron 82, April 16, 2014 ª2014 Elsevier Inc.expression can improve the HD phenotype in the R6/2 mouse
model suggests that targeting the uptake deficit in isolation
may provide at least some therapeutic benefit to HD patients
(Miller et al., 2008).
Signaling Pathways Associated with Extrasynaptic NMDARs
and HD Pathogenesis. Since the discovery of the underlying
genetic cause of HD, there has been a wealth of information
demonstrating transcriptional deficiencies as a result of mHtt
expression (Sugars and Rubinsztein, 2003). The Htt protein inter-
acts with a large array of intracellular binding partners involved in
many aspects of cellular function (Shirasaki et al., 2012). Altered
binding of mHtt with some of these partners probably contrib-
utes to the transcriptional deficits in HD. For example, mHtt
binds CBP more strongly than does Htt, and this enhanced
binding prevents CBP nuclear entry, thereby suppressing
CREB/CBP-mediated transcription (Cong et al., 2005; Nucifora
et al., 2001; Steffan et al., 2000). In addition, the enhanced extra-
synaptic NMDAR signaling in HD contributes to CREB shutoff;
NMDA treatment after synaptic NMDAR preblock in cultured
neurons decreases nuclear pCREB to a greater extent in cultures
from HD mice (Milnerwood et al., 2012), and low-dose meman-
tine treatment restores pCREB in HD mouse striatum to
wild-type levels (Dau et al., 2014; Milnerwood et al., 2010). These
findings offer hope that targeting extrasynaptic NMDARsmay be
of benefit to HD patients even in the continued presence of mHtt
expression.
The increased association between extrasynaptically located
GluN2B and PSD-95 in HD suggests the possibility that down-
stream nitric oxide signaling may play a critical role in mHtt-
induced toxicity (Sattler et al., 1999). However, it was shown
that while this interaction does indeed contribute to the patho-
genesis of HD, it does so in amanner that is independent of nitric
oxide signaling (Fan et al., 2009). Rather, striatal neuron toxicity
in HD is highly dependent on p38 MAPK signaling; p38 MAPK
inhibition or disruption of the PSD-95/GluN2B interaction
completely abolishes the enhanced NMDA-mediated cell death
that is observed in cultured striatal neurons from YAC128 mice
(Fan et al., 2012). In support of an extrasynaptic NMDAR involve-
ment, memantine treatment of YAC128micewas recently shown
to restore p38 MAPK activity back to wild-type levels (Dau et al.,
2014). Extrasynaptic NMDAR stimulation also increases the
expression of Rhes, a striatally enriched protein that contributes
to HDpathogenesis by inducing sumoylation and disaggregation
of mHtt (Okamoto et al., 2009; Subramaniam et al., 2009). The
enrichment of Rhes in the striatum has been proposed to explain
the enhanced vulnerability of striatal neurons to the Htt mutation
and makes Rhes an attractive target for the treatment of HD
(Mealer et al., 2013).
There is recent interest in the possibility that enhanced extra-
synaptic NMDAR activity can promote further NMDAR trafficking
to, and/or stabilization within, extrasynaptic sites in a potentially
toxic positive feedback cycle. For example, calpain activity is
increased after extrasynaptic but not synaptic NMDAR stimula-
tion (Xu et al., 2009) and is elevated in the YAC128 model of
HD at presymptomatic ages (Dau et al., 2014; Gladding et al.,
2012). These findings raise the possibility that enhanced extrasy-
naptic NMDAR tone in HD may promote elevated basal calpain
activity. On the other hand, calpain inhibition reverses NMDAR
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promotes extrasynaptic NMDAR expression, possibly through
calcium-dependent cleavage of GluN2B subunits (Gladding
et al., 2012; Gladding and Raymond, 2011). However, this ap-
pears to be true only at early presymptomatic stages of disease
progression (Dau et al., 2014). Similarly, expression of peroxi-
some proliferator-activated receptor gamma coactivator
1-alpha (PGC-1a) is reduced by mHtt through direct asso-
ciations with the promoter (Cui et al., 2006), as well as via
extrasynaptic NMDARs (Okamoto et al., 2009). Interestingly,
siRNA-based knockdown of PGC-1a increases extrasynaptic
NMDAR currents and vulnerability to excitotoxicity in cultured
neurons, whereas PGC-1a overexpression has the opposite
effect (Puddifoot et al., 2012).
Synaptic Plasticity in HD. HD is associated with debilitating
cognitive deficits that often appear prior to the onset of overt
motor symptoms (Stout et al., 2011; Van Raamsdonk et al.,
2005). This is likely to result from underlying deficits in synaptic
plasticity, which have been observed in mouse models (Milner-
wood et al., 2006; Murphy et al., 2000; Usdin et al., 1999) as
well as HD patients (Orth et al., 2010). Specifically, in HD mice,
impaired LTP is readily observed at the CA3-to-CA1 synapse
and correlates with poor performance on hippocampal-depen-
dent learning tasks. Much remains to be investigated with regard
to the mechanisms underlying the plasticity impairment in HD.
However, there appears to be an important role for BDNF, as
treatments that upregulate BDNF, or direct exogenous BDNF
application, restore LTP and cognitive performance in HD mice
(Lynch et al., 2007; Simmons et al., 2009). There is a relative
lack of BDNF production in HD that is at least in part attributed
to a loss of function of the nonpathogenic Htt protein (Gauthier
et al., 2004; Zuccato et al., 2001). Although it has yet to be tested,
it is quite possible that extrasynaptic NMDAR activity also con-
tributes to the BDNF reduction and/or the impairment in synaptic
plasticity. Asmentioned, BDNF is a downstream target of CREB,
and the basal pCREB reduction in the YAC model of HD is
restored by memantine treatment (Milnerwood et al., 2010).
Thus, it is of interest for future studies to determine whether
increasing glutamate uptake and/or decreasing extrasynaptic
NMDAR signaling can restore Hebbian plasticity and cognitive
capabilities in HD.
Ischemia
It has long been known that ischemic events increase the extra-
cellular concentration of glutamate to toxic levels, which appears
to be mediated in large part by decreased glutamate uptake and
reversed glutamate transport (Choi and Rothman, 1990; Jabau-
don et al., 2000; Rossi et al., 2000), as well as increased presyn-
aptic vesicular release (Fleidervish et al., 2001). Thus, in light of
research over the last decade demonstrating the importance of
extrasynaptic NMDARs to excitotoxic cell death, there has
been recent interest in determining whether the localization of
surface NMDARs can also negatively impact neuronal health
after ischemic insults. Research in cell culture has shown that
oxygen-glucose deprivation, conditions simulating ischemia,
can activate extrasynaptic NMDARs and decrease CREB phos-
phorylation (Hardingham et al., 2002) and that pharmacological
reversal of glutamate transport triggers cell death via extrasy-
naptic NMDAR activation (Gouix et al., 2009). Oxygen-glucosedeprivation was also found to induce extrasynaptic NMDAR-
mediated slow inward currents in hippocampal neurons that
are dependent upon astrocytic calcium waves, further suggest-
ing that glial glutamate release during energy deprivation can
activate NMDARs outside the synapse. In vivo, death-associ-
ated protein kinase 1 (DAPK1) increases its association with
GluN2B but not GluN2A subunits after ischemia, resulting in
enhanced GluN2B phosphorylation and extrasynaptic NMDAR
currents (Tu et al., 2010). Preventing astrocytic calcium waves,
selective blockade of GluN2B-containing NMDARs, genetic
deletion of DAPK1, or peptide-mediated disruption of the
DAPK1-GluN2B interaction were all found to significantly reduce
infarct volume after ischemia (Dong et al., 2013; Gotti et al., 1988;
Tu et al., 2010). Moreover, in rodents and nonhuman primates,
disrupting signaling downstream of NMDAR activity with the
Tat-NR2B9c peptide, which preferentially disrupts GluN2B inter-
actions with postsynaptic MAGUKs including PSD-95, reduces
infarct volume when administered after an ischemic event (Aarts
et al., 2002; Cook et al., 2012).
After extrasynaptic but not synaptic NMDAR activation, the
expression of a calcium-activated chloride channel, Clca1, is
upregulated, and overexpressing Clca1 in hippocampal neurons
causes cell death (Zhang et al., 2007). Interestingly, extra-
synaptic NMDAR-dependent Clca1 expression is upregulated
after oxygen-glucose deprivation, and bilateral carotid occlusion
can also increase Clca1 mRNA (Wahl et al., 2009). Additional
intracellular signaling mechanisms implicated in ischemic cell
death include PTEN monoubiquitination and nuclear transloca-
tion, as well as activation of calpains, p38 and JNK MAPKs,
FoxO3a, and sterol regulatory element binding protein-1
(SREBP1; Dick and Bading, 2010; Koumura et al., 2008; Ning
et al., 2004; Taghibiglou et al., 2009; Zhang et al., 2013; and
reviewed in Lai et al., 2011), all of which can be triggered by
GluN2B and/or extrasynaptic NMDAR activation (Dick and Bad-
ing, 2010; Hardingham and Bading, 2010; Taghibiglou et al.,
2009; Zhang et al., 2013).
While the aforementioned studies point to a critical involve-
ment of extrasynaptic NMDARs in ischemic cell death, recent
findings suggest that the respective roles for synaptic and extra-
synaptic NMDARs in survival and death in ischemia are far from
black and white. On the one hand, selective synaptic NMDAR
activation after energy deprivation can provide neuroprotection
by increasing the nuclear calcium- and CREB-dependent
expression of the prosurvival transcriptional repressor Atf3
(Zhang et al., 2011). On the other hand, a recent report demon-
strates that synaptic NMDARs may contribute to hypoxic cell
death. Wroge and colleagues show that although hypoxia-
induced cell death in cultured hippocampal neurons can be
blocked by low concentrations of memantine, it is due to
memantine’s actions on synaptic rather than extrasynaptic
NMDARs and that synaptic NMDAR activity is actually the major
contributor to cell death in their model (Wroge et al., 2012). How-
ever, it should be noted that these experiments combined
hypoxic conditions with magnesium-free solutions, probably
providing a level of tonic synaptic NMDAR activation that would
not be observed in either physiological or pathological condi-
tions in the human brain. In such a case, it is not overly surprising
that memantine demonstrated significant synaptic NMDARNeuron 82, April 16, 2014 ª2014 Elsevier Inc. 287
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NMDARs in OGD-induced excitotoxicity was similarly performed
in zero-magnesium solutions (Sattler et al., 2000). Nonetheless,
these studies demonstrate the ability for synaptic NMDARs to
signal to cell death under certain experimental conditions that
promote their tonic activation.
Pannexin hemichannel opening has been linked to ischemic
cell death by promoting large anoxic depolarizations after
NMDAR and Src family kinase activation (Thompson et al.,
2006; Weilinger et al., 2012). Similarly, NMDAR activation also
increases calcium influx through TRPVM7 channels that contrib-
utes to ischemic cell death (Aarts et al., 2003). Presently, it
remains unknown whether synaptic or extrasynaptic NMDARs
display preferential association with pannexin hemichannels
and TRPVM7 channels. In all, there is good evidence suggesting
that tonic NMDAR activation after a combination of enhanced
vesicular release and impaired/reversed uptake of glutamate
represents a major contributor to ischemic cell death. In such a
case, an appropriate therapeutic strategy would be to achieve
rapid reversal of the glutamate buildup as soon as possible after
an ischemic event.
Extrasynaptic NMDAR Involvement inOther Disorders of
the CNS
Evidence suggests that extrasynaptic NMDAR activity can also
play a prominent role in the cell death associated with other
CNS disorders. Excessive extracellular glutamate levels are
observed after traumatic brain injury (TBI) (Baethmann et al.,
1989; Katayama et al., 1990) and mechanical stretch injury to
cultured cortical neurons was recently found to augment extrasy-
naptic GluN2B-containing NMDARcurrents (Ferrario et al., 2013).
Furthermore, decreased synaptic GluN2B content is also
observed after TBI, further shifting the balance from synaptic to
extrasynaptic NMDAR signaling (Park et al., 2013). Similarly, sta-
tus epilepticus has long been known to induce delayed cell death
and cognitive decline, and a role of extrasynaptic NMDARs in this
process has been uncovered. Epileptiform activity increases as-
trocytic calcium, resulting in glial glutamate release and extrasy-
naptic GluN2B-containing NMDAR activation (Ding et al., 2007).
Electronmicroscopyhasdemonstratedan increaseanddecrease
in GluN2B content outside and inside the synapse, respectively,
after experimental epilepsy in rats, andpharmacologicalblockade
of GluN2B-containing NMDARs is neuroprotective in this model
(Frasca et al., 2011). Moreover, as extrasynaptic NMDARs
respond to glial glutamate release, it is possible that their activa-
tion is critical to the synchronized neuronal activity associated
with epileptic seizures (Fellin et al., 2004; Tian et al., 2005).
Conclusions
Substantial evidence suggests a dichotomy in NMDAR function
based largely on their subcellular localization and subunit
composition. This dichotomy is supported by demonstrations
of an extrasynaptic, GluN2B-containing NMDAR involvement in
the cell death associated with neurodegenerative diseases and
acute CNS injury, including AD, HD, ischemia, TBI, and epilepsy.
In each case, cell death appears to be mediated at least in part
by extrasynaptic NMDAR activation after enhanced glutamate
spillover, glutamate release from glia, and/or an upregulation of288 Neuron 82, April 16, 2014 ª2014 Elsevier Inc.NMDARs at extrasynaptic sites. Some of these disorders are
also associated with decreased synaptic NMDAR content or
activity, further shifting the balance in favor of prodeath extrasy-
naptic NMDAR signaling.While acceptance of the NMDAR local-
ization hypothesis is not universal, the bulk of data suggest that
localization is a major component of a hierarchy of factors that
contribute to NMDAR-induced excitotocity. Advancing our un-
derstanding of these mechanisms in disease states will help
design better therapeutics to restore NMDAR balance by
decreasing extracellular glutamate spillover/release and tonic
NMDAR activation, selectively blocking extrasynaptic NMDARs
or their downstream signaling or by enhancing cell-survival
NMDAR signaling.
While it is much too simple to characterize AD as hippocam-
pal-specific and HD as striatal-specific diseases, both of these
neurodegenerative diseases do show substantial differences in
neurodegeneration throughout the neuroaxis. Thus, it will be of
interest for future studies to determine whether enhanced extra-
synaptic NMDAR activity is associated specifically with those
areas affected in these disease states. Indeed, it was recently
shown that GLT-1 palmitoylation, and therefore glutamate up-
take capacity, in HD is impaired in the striatum and cortex, two
regions highly sensitive to the effects of mHtt, while no palmitoy-
lation deficits were observed in the relatively resistant cere-
bellum (Huang et al., 2010). Furthermore, it is unknown whether
extrasynaptic NMDAR activity affects all neuronal subtypes in
the same way; the large majority of work regarding the localiza-
tion hypothesis has been conducted on hippocampal and, in the
context of HD, striatal neurons.
The sheer diversity of NMDARs (Paoletti et al., 2013) com-
plicates comparisons of the literature under different experi-
mental conditions and, perhaps not surprisingly, the localization
hypothesis remains a controversial topic. Nonetheless, meman-
tine is well-tolerated and FDA approved and has shown clinical
benefit in moderate-to-severe AD cases, likely through either
the preferential blockade of extrasynaptic NMDARs or by pre-
venting tonic NMDAR activity, be it synaptic or extrasynaptic.
Going forward, it is well worth a coordinated effort to fully under-
stand the NMDAR involvement in cell death and survival, as it
may ultimately lead to successful treatments for several disor-
ders of the nervous system.
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